Nuplazid Shows Sustained Easing of Psychosis in Patients in Phase 3 Trial

Nuplazid Shows Sustained Easing of Psychosis in Patients in Phase 3 Trial
Daily use of Nuplazid (pimavanserin) leads to strong and sustained reductions in the frequency and severity of hallucinations and delusions in people with Parkinson’s disease psychosis, according to data from a long-term extension study. These findings, “Improvement and Durability in SAPS-PD Assessment over 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis,” were presented at the at the 2020 American ... read more
Source: Parkinson’s News TodayPublished on 2020-06-08By Joana Carvalho, PhD